Analysis of dermoscopic changes of blue nevi on digital follow-up: A 21-year retrospective cohort study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
13
09
2022
accepted:
05
01
2023
medline:
17
4
2023
pubmed:
26
1
2023
entrez:
25
1
2023
Statut:
ppublish
Résumé
Blue nevi are benign dermal melanocytic proliferations that are often easy to recognize clinically. Rarely, these lesions can display atypical features, suggesting the presence of a malignant blue nevus or mimicking cutaneous metastases of melanoma. To describe the clinical evolution of blue nevi over time and to assess the need for monitoring these lesions. We conducted a retrospective cohort study of 103 patients who were followed between December 1998 and November 2019. An artificial intelligence algorithm was used to identify blue nevi from the databases of two digital epiluminescence devices. Changes in the area of each lesion were calculated with a segmentation neural network. We included 123 blue nevi from 103 patients. Most of the lesions segmented, 99 (91.7%), were considered stable. Of the 9 (8.3%) growing blue nevi identified, 2 (1.85%) showed significant growth. The studied growing blue nevi turned out to be cellular blue nevi, presented with a low tumour mutation burden and GNAQ c.626A>T alteration was identified in both lesions. Some clinical variants of blue nevi might not be included. Most blue nevi remain stable during their evolution. Rarely, they can show progressive growth, although histopathological or molecular signs of malignancy have not been identified.
Sections du résumé
BACKGROUND
BACKGROUND
Blue nevi are benign dermal melanocytic proliferations that are often easy to recognize clinically. Rarely, these lesions can display atypical features, suggesting the presence of a malignant blue nevus or mimicking cutaneous metastases of melanoma.
OBJECTIVE
OBJECTIVE
To describe the clinical evolution of blue nevi over time and to assess the need for monitoring these lesions.
METHODS
METHODS
We conducted a retrospective cohort study of 103 patients who were followed between December 1998 and November 2019. An artificial intelligence algorithm was used to identify blue nevi from the databases of two digital epiluminescence devices. Changes in the area of each lesion were calculated with a segmentation neural network.
RESULTS
RESULTS
We included 123 blue nevi from 103 patients. Most of the lesions segmented, 99 (91.7%), were considered stable. Of the 9 (8.3%) growing blue nevi identified, 2 (1.85%) showed significant growth. The studied growing blue nevi turned out to be cellular blue nevi, presented with a low tumour mutation burden and GNAQ c.626A>T alteration was identified in both lesions.
LIMITATIONS
CONCLUSIONS
Some clinical variants of blue nevi might not be included.
CONCLUSIONS
CONCLUSIONS
Most blue nevi remain stable during their evolution. Rarely, they can show progressive growth, although histopathological or molecular signs of malignancy have not been identified.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
914-921Subventions
Organisme : Fondo de Investigaciones Sanitarias
ID : PI18/00419
Organisme : Fondo de Investigaciones Sanitarias
ID : PI18/01077
Organisme : Generalitat de Catalunya
ID : 2017/SGR1134
Organisme : CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain
Organisme : ISCIII-Subdireccion General de Evaluacion and European Regional Development Fund (ERDF)
Informations de copyright
© 2023 European Academy of Dermatology and Venereology.
Références
Martin RCW, Murali R, Scolyer RA, Fitzgerald P, Colman MH, Thompson JF. So-called “malignant blue nevus”: a clinicopathologic study of 23 patients. Cancer. 2009;115(13):2949-55. https://doi.org/10.1002/cncr.24319
Daltro LR, Yaegashi LB, Freitas RA, Fantini BC, Souza CS, Universidade de São Paulo, Brazil, et al. Atypical cellular blue nevus or malignant blue nevus? An Bras Dermatol. 2017;92(1):110-2. https://doi.org/10.1590/abd1806-4841.20174502
Sugianto JZ, Ralston JS, Metcalf JS, McFaddin CL, Smith MT. Blue nevus and “malignant blue nevus:” a concise review. Semin Diagn Pathol. 2016;33(4):219-24. https://doi.org/10.1053/j.semdp.2016.04.006
Zembowicz A, Phadke PA. Blue nevi and variants: an update. Arch Pathol Lab Med. 2011;135(3):327-36. https://doi.org/10.5858/2009-0733-RA.1
Kachare SD, Agle SC, Englert ZP, Zervos EE, Vohra NA, Wong JH, et al. Malignant blue nevus: clinicopathologically similar to melanoma. Am Surg. 2013;79(7):651-6.
Ferrara G, Soyer HP, Malvehy J, Piccolo D, Puig S, Sopena J, et al. The many faces of blue nevus: a clinicopathologic study. J Cutan Pathol. 2007;34(7):543-51. https://doi.org/10.1111/j.1600-0560.2006.00650.x
Fei WM, Li CX, Cui Y. Diagnostic value of dermoscopy combined with reflectance confocal microscopy for clinically equivocal blue nevus. Chin Med J (Engl). 2020;133(17):2116-8. https://doi.org/10.1097/CM9.0000000000001007
Plaza JA, Torres-Cabala C, Evans H, Diwan HA, Suster S, Prieto VG. Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum. Am J Dermatopathol. 2010;32(2):129-36. https://doi.org/10.1097/DAD.0b013e3181b34a19
Busam KJ. Metastatic melanoma to the skin simulating blue nevus. Am J Surg Pathol. 1999;23(3):276-82. https://doi.org/10.1097/00000478-199903000-00005
Roh MR, Eliades P, Gupta S, Tsao H. Genetics of melanocytic nevi. Pigment Cell Melanoma Res. 2015;28(6):661-72. https://doi.org/10.1111/pcmr.12412
Cohn DA, Ghahramani Z, Jordan MI. Active learning with statistical models. J Artif Intell Res. 1996;4:129-45. https://doi.org/10.1613/jair.295
Tan M, Le QV. EfficientNet: rethinking model scaling for convolutional neural networks. ArXiv190511946 Cs Stat. Published online September 11, 2020 [cited 2021 Dec 19]. Available from: http://arxiv.org/abs/1905.11946
Finlayson GD, Trezzi E. Shades of gray and colour constancy. Color Imaging Conf. 2004;2004(1):37-41.
Ronneberger O, Fischer P, Brox T. U-net: convolutional networks for biomedical image segmentation. ArXiv150504597 Cs. Published online May 18, 2015. [cited 2021 Dec 19]. Available from: http://arxiv.org/abs/1505.04597
Tschandl P, Rosendahl C, Kittler H. The HAM10000 dataset, a large collection of multi-source dermatoscopic images of common pigmented skin lesions. Sci Data. 2018;5(1):180161. https://doi.org/10.1038/sdata.2018.161
Codella N, Rotemberg V, Tschandl P, et al. Skin lesion analysis toward melanoma detection 2018: a challenge hosted by the international skin imaging collaboration (ISIC). ArXiv190203368 Cs. Published online March 29, 2019. [cited 2021 Dec 19]. Available from: http://arxiv.org/abs/1902.03368
Deng J, Dong W, Socher R, et al. ImageNet: a large-scale hierarchical image database. In: 2009 IEEE Conference on Computer Vision and Pattern Recognition; 2009. p. 248-55. https://doi.org/10.1109/CVPR.2009.5206848
Zhao C, Jiang T, Ju JH, et al. TruSight oncology 500: enabling comprehensive genomic profiling and biomarker reporting with targeted sequencing. bioRxiv; 2020:2020.10.21.349100. [cited 2022 Feb 18]. Available from: https://www.biorxiv.org/content/.
Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv13033997 Q-Bio. Published online May 26, 2013. [cited 2022 Feb 18]. Available from: http://arxiv.org/abs/1303.3997
Pisces. Illumina; 2021. [cited 2022 Feb 18]. Available from: https://github.com/Illumina/Pisces.
Stromberg M, Roy R, Lajugie J, et al. Nirvana: clinical grade variant annotator. In: Proceedings of the 8th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics. ACM-BCB'17. Association for Computing Machinery; 2017. p. 596. https://doi.org/10.1145/3107411.3108204
RStudio Team. RStudio: integrated development for R. Boston, MA: RStudio, PBC; 2020 http://www.rstudio.com/
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Core team; 2020.
Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10(1):25. https://doi.org/10.1186/s13073-018-0531-8
Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, et al. Molecular genomic profiling of melanocytic nevi. J Invest Dermatol. 2019;139(8):1762-8. https://doi.org/10.1016/j.jid.2018.12.033
Martins da Silva V, Martinez-Barrios E, Tell-Martí G, Dabad M, Carrera C, Aguilera P, et al. Genetic abnormalities in large to giant congenital nevi: beyond NRAS mutations. J Invest Dermatol. 2019;139(4):900-8. https://doi.org/10.1016/j.jid.2018.07.045
Rodríguez-Jiménez P, Mayor-Sanabria F, Rütten A, Fraga J, Llamas-Velasco M. Agminated blue nevus: GNAQ mutations and beyond. Actas Dermosifiliogr. 2021;112(1):95-7. https://doi.org/10.1016/j.ad.2019.05.011
Murali R, McCarthy SW, Scolyer RA. Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. Adv Anat Pathol. 2009;16(6):365-82. https://doi.org/10.1097/PAP.0b013e3181bb6b53
Guadagni M, Nazzari G. Clinical and dermoscopic features of an evolving deep-penetrating nevus. Arch Dermatol. 2005;141(11):1490. https://doi.org/10.1001/archderm.141.11.1490
de la Fouchardiere A, Blokx W, van Kempen LC, Luzar B, Piperno-Neumann S, Puig S, et al. ESP, EORTC, and EURACAN expert opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Arch Int J Pathol. 2021;479(1):3-11. https://doi.org/10.1007/s00428-020-03005-1
Chan MP, Andea AA, Harms PW, Durham AB, Patel RM, Wang M, et al. Genomic copy number analysis of a spectrum of blue nevi identifies recurrent aberrations of entire chromosomal arms in melanoma ex blue nevus. Mod Pathol. 2016;29(3):227-39. https://doi.org/10.1038/modpathol.2015.153